Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results

Eli Lilly and Company (LLY) received a price target increase to $1,400 from $1,350 by Barclays following strong first-quarter results. Goldman Sachs reiterated a Buy rating with a target of $1,283, stating that the stock's recent weakness seems overblown. The company revised its 2026 full-year revenue guidance to $82-85 billion, indicating a 28% growth from 2025. Additionally, LLY's non-GAAP EPS is estimated between $35.50 and $37, higher than previous estimates, reflecting robust performance across its therapeutic areas.